Friday, January 28, 2011

IOL CHEMICALS AND PHARMACEUTICALS - PANTAPRAZOLE RABEPRAZOLE MANUFACTURING FACILITY COMMISSIONING AND IBUPROFEN APPROVAL IN REGULATED MARKETS WILL DRIVE THE COMPANY TO NEW LEVELS

IOL Chemcials and pharmaceuticals is one of the lesser known stocks, in the API space.
IOL is one of the lowest cost producer of ibuprofen in the world. With the recent EU approval, the volumes and price realization for ibuprofen will  improve upto 1.5 times from current levels.  IOL being fully integrated as far as ibuprofen is concerned, they have complete control over costs.  US approval for ibuprofen facility is also expected.
Besides ibuprofen, they will also be commissioning their PPI manufacturing facilities in the coming months.  With the PPI class expected to get genericised and go OTC over the next few years, the volume growth for this market will be phenomenal.

Over a period of 2-3 years, we can expect tribling of sales base and quadrupling of profit base.
Great opportunity to get into the stock now.